{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T20:53:52Z","timestamp":1777668832913,"version":"3.51.4"},"reference-count":38,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["TCRM"],"DOI":"10.2147\/tcrm.s388324","type":"journal-article","created":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T03:15:14Z","timestamp":1684379714000},"page":"413-423","source":"Crossref","is-referenced-by-count":8,"title":["Clinical Utility of Deucravacitinib for the Management of Moderate to Severe Plaque Psoriasis"],"prefix":"10.2147","volume":"Volume 19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1283-4665","authenticated-orcid":true,"given":"Joy Q","family":"Jin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riley K","family":"Spencer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5643-2396","authenticated-orcid":true,"given":"Vidhatha","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tina","family":"Bhutani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7883-6439","authenticated-orcid":true,"given":"Wilson","family":"Liao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2023,5]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1001\/JAMADERMATOL.2021.2007","volume":"157","author":"Armstrong","year":"2021","journal-title":"JAMA Dermatol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.1016\/J.JID.2021.02.743","volume":"141","author":"Yan","year":"2021","journal-title":"J Invest Dermatol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1056\/NEJMOA021359","volume":"349","author":"Heydendael","year":"2003","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/NRDP.2016.82","volume":"2","author":"Greb","year":"2016","journal-title":"Nat Rev Dis Prim"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1001\/JAMA.2020.4006","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.3390\/IJMS20061475","volume":"20","author":"Rendon","year":"2019","journal-title":"Int J Mol Sci"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0378-1119(02)00398-0","volume":"285","author":"Kisseleva","year":"2002","journal-title":"Gene"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.4049\/JIMMUNOL.1800013","volume":"201","author":"Hawkes","year":"2018","journal-title":"J Immunol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3389\/FIMMU.2019.02342","volume":"10","author":"Howell","year":"2019","journal-title":"Front Immunol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1248\/BPB.B21-00609","volume":"44","author":"Muromoto","year":"2021","journal-title":"Biol Pharm Bull"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1126\/SCITRANSLMED.AAW1736","volume":"11","author":"Burke","year":"2019","journal-title":"Sci Transl Med"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1080\/1744666X.2022.2008240","volume":"18","author":"Abduelmula","year":"2021","journal-title":"Expert Review of Clinical Immunology"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1007\/S40265-022-01796-Y","volume":"82","author":"Hoy","year":"2022","journal-title":"Drugs"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1007\/S13555-021-00596-8","volume":"11","author":"Chimalakonda","year":"2021","journal-title":"Dermatol Ther (Heidelb)"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.4049\/JIMMUNOL.1901477","volume":"204","author":"Gadina","year":"2020","journal-title":"J Immunol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/NRD.2017.201","volume":"16","author":"Schwartz","year":"2017","journal-title":"Nat Rev Drug Discov"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1136\/BMJ.N71","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/J.JAAD.2011.01.022","volume":"66","author":"Robinson","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1111\/JDV.12106","volume":"28","author":"Mattei","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1111\/CTS.13435","volume":"16","author":"Catlett","year":"2023","journal-title":"Clin Transl Sci"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1136\/ANNRHEUMDIS-2021-221664","volume":"81","author":"Mease","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"ref22","unstructured":"CASP CHECKLISTS - CASP - critical appraisal skills programme. Available from: https:\/\/casp-uk.net\/casp-tools-checklists\/. Accessed September 21, 2022."},{"key":"ref23","unstructured":"Cochrane Training. Chapter 10: analysing data and undertaking meta-analyses. Available from: https:\/\/training.cochrane.org\/handbook\/current\/chapter-10. Accessed March 15, 2023."},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1056\/NEJMOA1806382\/SUPPL_FILE\/NEJMOA1806382_DATA-SHARING.PDF","volume":"379","author":"Papp","year":"2018","journal-title":"N Engl J Med"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/J.JAAD.2022.07.002","volume":"88","author":"Armstrong","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/J.JAAD.2022.08.061","volume":"88","author":"Strober","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/S13555-021-00649-Y","volume":"12","author":"Tha\u00e7i","year":"2022","journal-title":"Dermatol Ther (Heidelb)"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1111\/BJD.21048","volume":"187","author":"Mastorino","year":"2022","journal-title":"Br J Dermatol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1177\/24755303221131259","author":"Hadeler","year":"2022","journal-title":"J Psoriasis Psoriatic Arthritis"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/J.JAAD.2016.10.033","volume":"76","author":"Shalom","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1002\/JLB.5RU0519-145R","volume":"106","author":"Gremese","year":"2019","journal-title":"J Leukoc Biol"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1111\/IJD.15605","volume":"61","author":"Jo","year":"2022","journal-title":"Int J Dermatol"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1177\/12034754221141680\/ASSET\/IMAGES\/LARGE\/10.1177_12034754221141680-FIG2.JPEG","author":"Loo","year":"2022","journal-title":"J Cutan Med Surg"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1056\/NEJMOA2109927\/SUPPL_FILE\/NEJMOA2109927_DATA-SHARING.PDF","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"100075","DOI":"10.1016\/J.MEDIDD.2020.100075","volume":"9","author":"Makurvet","year":"2021","journal-title":"Med Drug Discov"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1016\/J.JAAD.2022.07.002","author":"Armstrong","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"ref37","unstructured":"Canada.ca. Health Canada safety review finds link between the use of Xeljanz and Xeljanz XR (tofacitinib) and increased risk of serious heart-related issues and cancer. Available from: https:\/\/recalls-rappels.canada.ca\/en\/alert-recall\/health-canada-safety-review-finds-link-between-use-xeljanz-and-xeljanz-xr-tofacitinib. Accessed March 15, 2023."},{"key":"ref38","unstructured":"FDA. FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death for JAK inhibitors that treat certain chronic inflammatory conditions. Available from: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-requires-warnings-about-increased-risk-serious-heart-related-events-cancer-blood-clots-and-death. Accessed March 15, 2023."}],"container-title":["Therapeutics and Clinical Risk Management"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=89801","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=89801","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T03:15:18Z","timestamp":1684379718000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/clinical-utility-of-deucravacitinib-for-the-management-of-moderate-to--peer-reviewed-fulltext-article-TCRM"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":38,"URL":"https:\/\/doi.org\/10.2147\/tcrm.s388324","relation":{},"ISSN":["1178-203X"],"issn-type":[{"value":"1178-203X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5]]}}}